Damora Therapeutics, Inc.
DMRA
NASDAQ·Healthcare·Biotechnology·Mkt cap $1.9B
$30.06
▲ +7.36%
P/E
—
Mkt Cap
$1.9B
52-Wk Range
$2.45–$38.33
52-Week Range
$2.45 - $38.33
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 872.8% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary small molecule inhibitor technology
- Novel target mechanisms (galectin-3 and LOXL2)
- Experienced management team with biotech expertise
- Strategic focus on high-unmet-need disease areas
Bear Case
1 risk
- Average volatility.
Growth
Stable outlook
Clinical trial advancement and regulatory milestones
Value
Deep value opportunity - significant discount to Healthcare Distribution peers
Momentum
Hot
+43.8% over 3m
Quality
Loss-making
Mixed fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying DMRA right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Oct 30, 2026
AUG 10, 2026
Reported EPS of -$0.39 vs -$0.41 consensus (+5.7% surprise).
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+5.7%
Revenue trend · last 8Q
—
—
—
—
—
—
—
—
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$0
$0
$0
$0
$0
$0
$0
$0
Margins · last 8Q
No margin history available.
Wall Street consensus
3 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: Wedbush · Jul 30, 2026
vs Industry
How DMRA stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related